Low-Temperature Metal Oxide Encapsulation for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions prepared by known methods exhibit reduced flowability and drug degradation during the preparation process, necessitating the development of new compositions and methods for encapsulating drugs with enhanced flowability, stability, and solubility.
Innovation Solution
A method involving sequential application of vaporous or gaseous metal precursors and oxidants with pump-purge cycles using inert gas at temperatures not exceeding 35°C, forming metal oxide layers around drug particles to enhance flowability and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known coating methods are used to encapsulate drugs, then drug encapsulation is achieved, but flowability is reduced and drug degradation occurs
Solution Approach 1:
The patent changes the temperature parameter from conventional high temperatures to below 35°C, which prevents drug degradation while enabling successful metal oxide coating formation. This temperature parameter change resolves the contradiction by allowing encapsulation without the harmful effects of thermal degradation.
Solution Approach 2:
The patent uses composite metal oxide materials (such as aluminum oxide, titanium oxide, zinc oxide) as coating layers encapsulating the drug core. These composite materials provide both protection against degradation and maintenance of flowability, resolving the contradiction between stability and manufacturability.
2Manufacturing precision
If higher temperatures are used in coating processes, then coating formation is enhanced, but drug degradation increases
Solution Approach 1:
The patent fundamentally changes the temperature parameter from conventional high temperatures to below 35°C. This parameter change enables coating formation through alternative mechanisms (such as chemical vapor deposition at low temperatures) that do not require thermal energy, thus achieving coating quality without drug degradation.
Solution Approach 2:
The patent replaces thermal-based coating mechanisms with chemical vapor deposition and other non-thermal chemical processes. This substitution allows coating formation without relying on thermal energy, thereby preventing drug degradation while maintaining coating integrity.
3Reliability
If conventional encapsulation methods are used, then drug protection is achieved, but solubility and functional drug fraction are reduced
Solution Approach 1:
The patent employs composite metal oxide coatings that provide protective functions while maintaining drug solubility and functionality. The specific metal oxides used (aluminum oxide, titanium oxide, etc.) create a protective barrier that does not interfere with drug performance, thus preserving functional drug fraction while achieving protection.
Solution Approach 2:
By changing the coating process parameters to low temperature operation, the patent prevents drug degradation that would otherwise reduce functional drug fraction. This parameter change ensures that the protective coating is formed without compromising the chemical integrity or solubility of the drug core.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces pharmaceutical compositions with improved flowability, solubility, and stability, reducing drug degradation and manufacturing costs while maintaining a high functional drug fraction.
Implementation Method 1
applying a vaporous or gaseous oxidant to the particles in the reactor
Implementation Method 2
applying a vaporous or gaseous metal precursor to the particles in the reactor
Implementation Method 3
performing one or more pump-purge cycles of the reactor using inert gas
Data Source
AI summary
A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. The temperature of the particles does not exceed 35° C. This produces a pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials.